Multi-Target Kinase Inhibitors for Vascular Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to unregulated tyrosine kinase signal transduction, such as diabetic retinopathy and age-related macular degeneration, often target single receptor tyrosine kinase pathways, which may not provide sufficient therapeutic effect, and there is a need for compounds that can effectively modulate or inhibit both VEGF and PDGF receptors to address these conditions.
Innovation Solution
Development of specific organic molecules that can block VEGF and/or PDGF receptors, represented by compounds of a general formula I, which are designed to inhibit tyrosine kinase signal transduction, thereby treating vascular proliferative disorders like diabetic retinopathy and age-related macular degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If single receptor tyrosine kinase pathways are targeted, then treatment simplicity is maintained, but therapeutic effect is insufficient
Solution Approach 1:
The patent applies universality by designing a single compound (formula I) that can simultaneously inhibit multiple receptor tyrosine kinase pathways including VEGFR, PDGFR, and FGFR. This multi-functional approach allows one drug molecule to target multiple disease-relevant kinases, thereby improving therapeutic effect while maintaining treatment simplicity through single-agent therapy
2Reliability
If multiple receptor tyrosine kinase pathways are targeted, then therapeutic effect is improved, but compound complexity increases
Solution Approach 1:
The patent merges multiple kinase inhibition functions into a single compound structure (formula I). By combining multiple pharmacophore elements within one molecular framework, the invention achieves simultaneous inhibition of VEGFR, PDGFR, and FGFR pathways without requiring combination therapy, thus improving therapeutic effect while avoiding the complexities of multiple drugs
3Reliability
If multiple receptor tyrosine kinase pathways are targeted, then therapeutic effect is improved, but development complexity increases
Solution Approach 1:
The patent employs preliminary action by pre-designing the compound structure (formula I) with multiple kinase binding capabilities built-in from the outset. Rather than developing separate inhibitors for each pathway and combining them later, the invention预先 incorporates multiple inhibition functions into a single molecular design, simplifying the overall drug development process while achieving multi-pathway therapeutic effects
Data Source
AI summary
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.